IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024428345, titled EMERGENCY EYE WASH, naming inventors Stewart Lebrun and Linda Nguyen of Lebrun Labs LLC. The application was accepted on 10 August 2026 and will be advertised in the Australian Official Journal of Patents on 27 August 2026.
The patent covers a shelf-stable two-part eyewash device for emergency treatment of corneal chemical exposure. The design keeps the active ingredient separate from the liquid portion until the moment of use, allowing rapid on-demand preparation of a buffered ascorbic acid solution. Claims cover both the device and the method of administration.
Patent Details
Claims at Acceptance
A shelf-stable two-part device that produces a buffered ascorbic acid eyewash solution for emergency treatment of corneal exposure to strong oxidizing or corrosive chemicals, with a delivery nozzle for application to one or both eyes.
The device of claim 1, wherein the solid and liquid portions are combined by shaking or inverting the device.
A device producing a buffered ascorbic acid eyewash solution across a range of concentrations and volumes, with a delivery nozzle for application to one or both eyes.
The device of claim 3, specifying the ascorbic acid concentration of the solid portion.
The device of claim 3, specifying an alternative ascorbic acid concentration of the solid portion.
The device of claim 3, wherein the buffering capacity of the liquid portion controls the final eyewash pH.
A method of administering the eyewash solution of claim 1 to a chemically exposed cornea within 10 minutes of exposure.
A method of administering the eyewash solution of claim 3 to a chemically exposed cornea within 10 minutes of exposure.
Significance
This patent strengthens Lebrun Labs LLC's intellectual property portfolio in emergency ocular first aid. The two-part shelf-stable design addresses a key limitation of conventional eyewash stations by keeping the active ingredient stable until the moment of use, enabling effective treatment immediately after a chemical splash. The patent term runs to 24 September 2044.